Journal of Integrative Oncology
ISSN: 2329-6771
Abstract



State of the art management of Radioactive-Iodine Refractory Di erentiated Thyroid Cancer (RAI-R DTC)

Naiyarat Prasongsook
MD, MS. Phramongkutklao Hospital, Bangkok, Thailand

Abstract:
Introduction: The treatment options for patients with radioactive-iodine refractory di erentiated thyroid cancer include observation, multi-tyrosine kinase inhibitors (MTKIs), and traditional chemotherapy. An appropriate initial treatment with MTKI is challenging in clinical practice that the benefits outweigh the risk of any adverse events. Treatment strategies for Radioactive-Iodine Refractory Di erentiated Thyroid Cancer: The activation of multiple downstream VEGFR signaling pathway, oncogenic mutated kinases (e.g. BRAF mutations), rearrangements of RET ,ALK, NTRK, and TERT promoter mutation are molecular mechanisms involved in RAI-R DTC. MTKIs demonstrated the clinical benefits either progression-free survival (11 to 18 months) or response rate (24-63%).

Sorafenib and lenvatinib were approved by FDA for treatment of RAI-R DTC. However, up to 60% of patients with MTKIs required a dose reduction due to adverse events (AEs). The most frequent AEs are hypertension, diarrhea, weight loss, musocitis, fatigue,hand-foot syndrome, alopecia, and diarrhea. Therefore, close monitoring for disease progression and TSH-suppressive therapy are appropriate treatment for those patients with asymptomatic metastatic disease, or slow growing tumor. Initiation of treatment with MTKIs should be considered in symptomatic disease or rapid growing tumor.

Conclusions: MTKIs demonstrate a promising approach. Sorafenib and lenvatinib have been approved by the FDA for the treatment of RAI-R DTC. However, multidisciplinary evaluation for adjustment made in order to take account of clinical benefit and risks should be performed before initiating MTKIs regarding to potential toxicities.

Biography:
Dr. Prasongsook has completed Thai Board of Medical Oncology from Ramathibodi Hospital, Bangkok, Thailand, then postdoctoral research fellowship in Medical Oncology at Mayo Clinic, and a master degree of Clinical Translational Science Program from Mayo Graduate School, Rochester, MN, USA. Current position is assistant professor in Medical Oncology unit at Phramongkutklao Hospital, Bangkok, Thailand. Research interests include all areas of care related to endocrine malignancies, with focusing on thyroid cancer, lung cancer, and nutraceutical approach in cancer treatment.

Publication of speakers:

1. Laowalert, suthanit & prasongsook, naiyarat & ativitasvas, touch & liwlompaisan, wisit & thanak, pongpan & techawathanawanna, north & khunprakant, rungrote & boonnim, kesawan & mavichak, viroon. (2020). Incidence and survival of malignancy following kidney transplantation at a single center in thailand. Transplantation. 104. S415-s415. 10.1097/01.tp.0000700720.77351.38.
2. Tienchaiananda, piyawan & nipondhkit, wipada & prasongsook, naiyarat. (2020). Olanzapine: is it enough for cinv prevention?. Annals of palliative medicine. 9. 43-43. 10.21037/apm-20-1018.
3. Laowalert, s & prasongsook, naiyarat & ativitasvas, t & liwlompaisan, w & thanak, p & techawathanawanna, n & khunprakant, r & mavichak, v. (2019). 210ohigh incidence and mortality of transitional cell carcinoma in thai kidney transplant patients. Annals of oncology. 30. 10.1093/annonc/mdz425.002.
4. Prasongsook, naiyarat & seetalarom, kasan & saichaemchan, siriwimon & udomdamrongkul, kitipong. (2019). A pilot study of using smartphone application versus routine follow up for patients' care in advanced non-small cell lung cancer (nsclc).. Journal of global oncology. 5. 9-9. 10.1200/jgo.2019.5.suppl.9.

Citation: Naiyarat Prasongsook; State of the art management of Radioactive-Iodine Refractory Di erentiated Thyroid Cancer (RAI-R DTC); Oncology Research 2020; November 23, 2020; 4:00PM IST